- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
Dandrit ‘s technique is based on Dendritic Cells, garland science made this easy-to-understand youtube video on the development of Dendritic Cells
http://www.youtube.com/watch?v=ZuccruG_79M
this stops at where the T-cells enters :)…
but don’t despair I’ve found another from KhanAcademy.org on the cytotoxic T-cells http://www.youtube.com/watch?v=xaz5ftvZCyI&feature=related (these are the cells that attack cancer-cells)
So far the only FDA approved vaccine is Provenge by Dendreon
http://www.youtube.com/watch?v=MTSc-hXxL3I
So far no video has been made on Dandrit’s MelCancerVac – lets hope a cash-infusion will change that – untill tehn we will have to make do with this written explanation of the process http://dandrit.dk/technology/vaccine-platform
About Stengaard
BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂
Related posts:
- Dandrit – a new Dendreon ? Sure looks like it ! Dandrit strengthens its European Patent base. This company has potential...
- While we wait for Dandrit and DKTI As some of you know, Dandrit is planning a merger...
One Response to Dendritic Cells explained, Provenge, Dandrit
Leave a Reply Cancel reply
Ongoing debate
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
Dendreon (DNDN) faces competition from other large companies such as Johnson/Johnson – here is an interesting contrarian article about the progress of J&J's Zytiga …. http://seekingalpha.com/article/642161-asco-data-…
The overall conclusion from this catfight is that cancer vaccine will be a focus area. I've no doubt that this will eventually mean that Dandrit will be swallowed by one of the major players.
Based on the fact that Dendreon seems to have most to gain by keeping cometitors out of the market taht they see as theirs (being first movers) I see clear advantages for Dendreon by aquiring Dandrit